Celltrion Inc
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 24
- Registration Number
- NCT05017168
- Locations
- 🇵🇱
Biokinetica S.A, Józefów, Poland
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 41
- Registration Number
- NCT05009368
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 37
- Registration Number
- NCT05002244
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 479
- Registration Number
- NCT04757376
- Locations
- 🇵🇱
AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Mazowieckie, Poland
🇪🇪East Tallinn Central Hospital-Ravi 18, Tallinn, Harjumaa, Estonia
🇱🇻Health Center 4-117 K. Barona Str, Riga, Latvia
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 348
- Registration Number
- NCT04739306
- Locations
- 🇸🇰
II. Ocna klinika SZU, F.D.Roosevelt Hospital, Banska Bystrica, Slovakia
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 509
- Registration Number
- NCT04673786
- Locations
- 🇪🇪
Clinical Research Centre, Tartu, Tartu Country, Estonia, Estonia
A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 1642
- Registration Number
- NCT04602000
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 18
- Registration Number
- NCT04593641
- Locations
- 🇰🇷
Incheon Medical Center, Incheon, Korea, Republic of
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 32
- Registration Number
- NCT04525079
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 30
- Registration Number
- NCT04512872
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
© Copyright 2024. All Rights Reserved by MedPath